Approvals in 2022: overall survival, dose optimization, new approvals and beyond

Nature Reviews Clinical Oncology, Published online: 23 February 2023; doi:10.1038/s41571-023-00741-6In 2022, the FDA approved numerous new drug and biologic agents, including targeted small molecules, immunotherapeutics, a gene therapy and a radiopharmaceutical. Several drug development challenges were also addressed, and key focus areas for the FDA Oncology Center of Excellence included ongoing monitoring of the Accelerated Approval programme and drug dose optimization.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research